RxDoctor Payments Data

Lisa Arcikowski, NP

Nurse Practitioner · Beverly, MANPI 1235374836

Payments from drug & device makers

$1,410in general payments, 2019–2025

Across 23 payments — averaging $61.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$598
  • Amgen$219
  • Gilead$161
  • Incyte Corporation$121
  • Johnson & Johnson$108
  • Astellas Pharma US Inc$76
  • plus $127 from 4 others

What the payments were for

  • Food & beverage$58742%
  • Education$82358%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,410 in reported general payments places this provider in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$44,460
Medicare patients
292
Services billed
471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide139$1,747,109
RevlimidLenalidomide60$944,673
ImbruvicaIbrutinib44$732,422
PomalystPomalidomide34$714,766
JakafiRuxolitinib Phosphate27$459,106
KisqaliRibociclib Succinate30$403,988
TagrissoOsimertinib Mesylate19$324,459
IbrancePalbociclib19$285,373
InlytaAxitinib13$261,965
BosulifBosutinib12$238,047
Abiraterone Acetate63$197,770
VenclextaVenetoclax12$91,972
EliquisApixaban86$80,317
XareltoRivaroxaban29$32,533
Anastrozole250$7,955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$20$714,76634 claims
Incyte CorporationJakafi$121$459,10627 claims
NovartisKisqali$23$403,98830 claims
AstraZenecaTagrisso$598$324,45919 claims
Johnson & JohnsonXarelto$108$32,53329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Beverly

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →